The massive secondary offering at a premium to market might provide a temporary floor, but the magnitude of dilution (more than doubling shares) will pressure the stock post-offering. Monitor for the over-allotment exercise and any insider buying signals. The patent litigation with Inspire remains a binary risk. Consider short-term bearish bias on supply overhang.
Price Chart
Executive Summary
Nyxoah is raising approximately $88.5 million net (€76.3 million) from a public offering of 55.2 million ordinary shares at $1.72 per share, representing a 126% increase in share count from the 43.7 million shares outstanding as of March 31, 2026. The offering price is a ~19% premium to the last closing price of $1.45. The company had only €25.9 million in cash and financial assets as of Q1 2026, with cash runway extending only into Q3 2026. Proceeds will fund US commercialization, R&D, and general corporate purposes. The massive dilution signals financial distress and overshadows any positive commentary about commercial traction or FDA approval.
Key Facts
- Offering of 55,232,558 ordinary shares at $1.72/share, raising $95.0M gross / $88.5M net
- Shares outstanding will increase from 43.7M to 98.9M (126% dilution); up to 107.2M if over-allotment exercised
- Stock last traded at $1.45 on June 5, 2026; offering price is ~19% premium
- Cash, cash equivalents, and financial assets were just €25.9M as of March 31, 2026, with accumulated deficit of €321.7M
- Cash runway expected only into Q3 2026 before this offering
- Company seeking to transition CEO to a US-based leader; ongoing patent litigation with Inspire Medical
- IPO-level dilution for a company with $63M market cap
Financial Impact
Immediate dilution of ~126% for existing shareholders; net proceeds of $88.5M extend runway but at extreme cost
Risk Factors
- Extreme dilution (126%+ increase in share count) will pressure EPS and ownership
- Company has no path to profitability; operating losses continue
- Patent litigation with Inspire Medical could disrupt US commercialization
- Leadership transition uncertainty with CEO search
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-071189 |
| Document: 0001104659-26-071189-index-headers.html | 0001104659-26-071189 |
| Document: 0001104659-26-071189-index.html | 0001104659-26-071189 |
| Document: 0001104659-26-071189.txt | 0001104659-26-071189 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $0.8950 $0.8220 | ▲ +8.16% | ▲ +6.98% | $0.8560 (+4.36%) |
Oct 19, 2026 8d ago | Press Release | $0.9540 $0.9400 | ▲ +1.47% | ▲ +1.80% | $0.8560 (+10.27%) |
Sep 22, 2026 5w ago | 6-K | $1.33 $1.27 | ▼ −4.51% | ▼ −4.43% | $0.8560 (−35.64%) |
Jun 23, 2026 18w ago | 6-K | $1.62 $1.63 | ▼ −0.62% | ▼ −0.47% | $0.8560 (+47.16%) |
Jun 11, 2026 19w ago | 6-K | $1.39 $1.55 | ▼ −11.51% | ▼ −9.75% | $0.8560 (+38.42%) |
Jun 8, 2026 20w ago | 6-K | $1.34 $1.31 | ▲ +2.24% | ▲ +0.66% | $0.8560 (+36.12%) |
Jun 8, 2026 20w ago | 424B5 | $1.39 $1.34 | ▲ +3.60% | ▲ +3.30% | $0.8560 (+38.42%) |
Jun 5, 2026 20w ago | Press Release | $1.45 $1.39 | ▲ +4.14% | ▲ +4.36% | $0.8560 (+40.97%) |
Jun 4, 2026 20w ago | 424B5 | $1.45 $1.39 | ▲ +4.14% | ▲ +4.36% | $0.8560 (+40.97%) |
May 20, 2026 22w ago | Press Release | $2.87 $2.87 | · 0.00% | ▼ −0.45% | $0.8560 (−70.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers